Compare Biogen Inc (BIIB) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Teucrium Wheat Fund — how do they compare? Biogen Inc trades at $208.74 (market cap $30.13B), while Teucrium Wheat Fund trades at $24.39. The key difference: Biogen Inc is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals.
| BIIB | WEAT | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.63 | $26.00 |
52-Week Low | $128.93 | $19.88 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
WEAT, the Teucrium Wheat Fund, trades at $24.42, up 1.71% today, with a bullish technical signal from moving averages. Recent news highlights a 9.9% monthly gain, driven by wheat price increases and USDA production cuts. The ETF's performance is closely tied to agricultural commodity markets and inflation trends.
Outlook remains influenced by supply dynamics and inflation; opportunities exist from sustained commodity strength, but risks include weather volatility and economic shifts that could pressure wheat prices and ETF returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
